Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 45

1.

[Gardnerella vaginalis bacteremia in a male patient].

Alidjinou EK, Bonnet I, Canis F, Dewulf G, Mazars E, Cattoen C.

Med Mal Infect. 2013 Oct;43(10):434-5. doi: 10.1016/j.medmal.2013.07.007. Epub 2013 Sep 6. French. No abstract available.

PMID:
24016769
2.

[Post-operative bacteremia caused by multidrug-resistant Aerococcus viridans in a patient with gall bladder cancer].

Tekin Koruk S, Bayraktar M, Ozgönül A, Tümer S.

Mikrobiyol Bul. 2010 Jan;44(1):123-6. Turkish.

PMID:
20455408
3.

Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.

Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S.

J Pediatr Hematol Oncol. 2009 Sep;31(9):635-41. doi: 10.1097/MPH.0b013e3181acd8cd.

PMID:
19684522
4.

Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.

Pereira CA, Petrilli AS, Carlesse FA, Luisi FA, da Silva KV, de Martino Lee ML.

J Microbiol Immunol Infect. 2009 Apr;42(2):141-7.

PMID:
19597646
5.

Are we finally ready for outpatient management of febrile neutropenia?

Saini S, Rosoff PM.

Pediatr Blood Cancer. 2007 Nov;49(6):765-6. No abstract available.

PMID:
17514730
6.

Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.

Ahmed N, El-Mahallawy HA, Ahmed IA, Nassif S, El-Beshlawy A, El-Haddad A.

Pediatr Blood Cancer. 2007 Nov;49(6):786-92.

PMID:
17366527
8.

A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.

Rossini F, Terruzzi E, Verga L, Larocca A, Marinoni S, Miccolis I, Giltri G, Isella M, Parma M, Pogliani EM.

Support Care Cancer. 2005 Jun;13(6):387-92. Epub 2004 Dec 15.

PMID:
15599778
9.

Allogeneic peripheral blood stem cell transplantation in patients with haematological malignancies.

Shamsi TS, Irfan M, Ansari SH, Farzana T, Khalid MZ, Panjwani VK, Baig MI, Shakoor N.

J Coll Physicians Surg Pak. 2004 Sep;14(9):522-6.

PMID:
15353134
10.

[Cefepime/amikacin in the empirical antibacterial therapy for patients with hemoblastosis of different forms].

Chudanova TV, Abdulkadyrov KM, Chebotkevich VN.

Antibiot Khimioter. 2003;48(7):29-32. Russian.

PMID:
14628576
11.

Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma.

Petrilli AS, Cypriano M, Dantas LS, Lee LM, Vercillo Luisi MF, Torres B Silva KV, Pires Pereira CA.

Braz J Infect Dis. 2003 Apr;7(2):111-20.

12.

Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen.

Girmenia C, Lo Coco F, Breccia M, Latagliata R, Spadea A, D'Andrea M, Gentile G, Micozzi A, Alimena G, Martino P, Mandelli F.

Leukemia. 2003 May;17(5):925-30.

PMID:
12750707
13.

Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.

Paganini H, Gómez S, Ruvinsky S, Zubizarreta P, Latella A, Fraquelli L, Iturres AS, Casimir L, Debbag R.

Cancer. 2003 Apr 1;97(7):1775-80.

14.

Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients.

Borbolla JR, López-Hernández MA, González-Avante M, DeDiego J, Trueba E, Alvarado ML, Jiménez RM.

Chemotherapy. 2001 Sep-Oct;47(5):381-4.

PMID:
11561142
15.

Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.

Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, Latella A, Firpo V, Casimir L, Armada A, Fernández C, Cáceres E, Debbag R.

Cancer. 2001 Apr 15;91(8):1563-7.

PMID:
11301406
16.

[Criteria of low risk of mortality in children with neutropenia and fever during cancer chemotherapy].

Paganini HR, Rodríguez Brieshcke T, Zubizarreta P, Latella A, Firpo V, Fernandez C, Armada A, Casimir L, Debbag R.

Medicina (B Aires). 2001;61(1):63-6. Spanish.

PMID:
11265626
17.

Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.

Ariffin H, Arasu A, Mahfuzah M, Ariffin WA, Chan LL, Lin HP.

J Paediatr Child Health. 2001 Feb;37(1):38-43.

PMID:
11168867
18.

Oral administration of cefixime to lower risk febrile neutropenic children with cancer.

Paganini HR, Sarkis CM, De Martino MG, Zubizarreta PA, Casimir L, Fernandez C, Armada AA, Rodriguez-Brieshcke MT, Debbag R.

Cancer. 2000 Jun 15;88(12):2848-52.

PMID:
10870071
19.

[Granulocyte colony-stimulating factor in the treatment of febrile neutropenia].

López-Hernández MA, Jiménez-Alvarado R, Borbolla-Escoboza R, de Diego Flores-Chapa J, Alvarado-Ibarra M, González-Avante M, Trueba-Chrysti ME, Anaya-Cuéllar I.

Gac Med Mex. 2000 Mar-Apr;136(2):99-105. Spanish.

PMID:
10815320
20.

Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit.

Girmenia C, Alimena G, Latagliata R, Morano SG, Celesti F, Coppola L, Spadea A, Tosti S, Mecarocci S, D'Elia GM, Tafuri A, Cimino G, Mandelli F.

Haematologica. 1999 Sep;84(9):814-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk